Tinengotinib Tablets Accept New Drug Application in China: A Significant Step Forward in Cancer Treatment TransThera Sciences has announced that the new drug application for Tinengotinib tablets has been accepted in China, marking progress in cholangiocarcinoma treatment.

Tinengotinib Tablets Accept New Drug Application in China: A Significant Step Forward in Cancer Treatment #China #Nanjing #oncology #TransThera #tinengotinib

Clinical Outcomes of Tinengotinib for Cholangiocarcinoma Published in The Lancet TransThera Sciences has published significant clinical trial results for tinengotinib in treating Cholangiocarcinoma, a challenging cancer. Discover these promising insights.

Clinical Outcomes of Tinengotinib for Cholangiocarcinoma Published in The Lancet #China #Nanjing #tinengotinib #Cholangiocarcinoma #TransThera_Sciences

TransThera's Tinengotinib Tablets Gain Priority Review for Cancer Treatment in China TransThera Sciences announces the inclusion of Tinengotinib tablets in the priority review list by China's National Medical Products Administration, potentially enhancing treatment options for cholangiocarcinoma.

TransThera's Tinengotinib Tablets Gain Priority Review for Cancer Treatment in China #China #Nanjing #TransThera #tinengotinib #Cholangiocarcinoma

Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social

TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma TransThera Sciences has published groundbreaking findings on tinengotinib, an innovative treatment for cholangiocarcinoma, revealing new insights into acquired resistance and potential therapies.

TransThera Unveils Promising Tinengotinib Research Against Cholangiocarcinoma #China #Nanjing #TransThera #tinengotinib #Cholangiocarcinoma

TransThera Presents Promising Clinical Data on Tinengotinib for Biliary Tract Carcinoma at 2024 ESMO Asia TransThera Sciences unveiled encouraging findings regarding tinengotinib in combination with atezolizumab for biliary tract carcinoma during the 2024 ESMO Asia Congress.

TransThera Presents Promising Clinical Data on Tinengotinib for Biliary Tract Carcinoma at 2024 ESMO Asia #China #Nanjing #TransThera #tinengotinib #biliary_tract_carcinoma